Brief: Guardant Health Receives FDA Approval For Guardant360® Cdx As A Companion Diagnostic For Arvinas And Pfizer’S Veppanu (Vepdegestrant) For Patients With Er+/Her2- Advanced Breast Cancer With Esr1 Mutations
04/05/2026 13:14
May 4 (Reuters) - Guardant Health Inc GH.O: GUARDANT HEALTH RECEIVES FDA APPROVAL FOR GUARDANT360® CDX AS A COMPANION DIAGNOSTIC FOR ARVINAS AND PFIZER’S VEPPANU (VEPDEGESTRANT) FOR PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER WITH ESR1 MUTATIONS Source text: ID:nBw8zNSt7a Further company coverage: GH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Guardant Health
See all newsBrief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
Grail's cancer blood test nears landmark FDA approval, but insurance coverage looms
US Health Secretary Kennedy Jr. adds eight new members to key health committee (updated)
Brief: US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
Brief: Guardant Health To Appeal Federal District Court Judgment